2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Classical hematology
1
Conditions
Thrombocytopenia
14
Leukemia, Myeloid, Acute
11
Leukemia
7
Myelodysplastic Syndromes
5
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Lymphocytic, Chronic, B-Cell
3
Jacobs syndrome
3
Sarcoma
2
Purpura, Thrombocytopenic, Idiopathic
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Hematologic Neoplasms
2
Congenital Abnormalities
2
Solid Tumor, Childhood
1
Recurrence
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Connective and Soft Tissue
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Rituximab
226
Cyclophosphamide
202
fludarabine phosphate
108
Peripheral Blood Stem Cell Transplantation
103
Filgrastim
87
Etoposide
76
Cytarabine
70
ibrutinib
68
Mycophenolic Acid
67
Bortezomib
66
Whole-Body Irradiation
63
Cyclosporine
63
Melphalan
59
Lenalidomide
59
Bendamustine Hydrochloride
58
Vincristine
53
Radiotherapy
53
fludarabine
52
Tacrolimus
50
Doxorubicin
48
Busulfan
48
Methotrexate
47
Antilymphocyte Serum
42
Prednisone
41
Carmustine
40
Dexamethasone
38
Granulocyte Colony-Stimulating Factor
33
venetoclax
32
acalabrutinib
31
zanubrutinib
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Mantle-Cell
×
eltrombopag
×
Clear all
NCT01500538
2016-02-15
VEIL
Peter MacCallum Cancer Centre, Australia
Phase 2
Terminated
1 enrolled